Effect of tamoxifen and raloxifene on the proliferative activity of the breast epithelium in premenopausal women [0.03%]
他莫昔芬和雷洛昔芬对绝经前女性乳腺上皮增殖活性的影响
Miliana T Lucato,Ruffo Freitas-Junior,Marise Ar Moreira et al.
Miliana T Lucato et al.
Objectives: To compare the effects of tamoxifen and raloxifene on the proliferative activity of normal breast tissue in premenopausal women as measured by Ki-67/MIB-1 expression. ...
Development of Interpretable Predictive Models for BPH and Prostate Cancer [0.03%]
可解释的良性前列腺增生和前列腺癌预测模型的发展
Pablo Bermejo,Alicia Vivo,Pedro J Tárraga et al.
Pablo Bermejo et al.
Background: Traditional methods for deciding whether to recommend a patient for a prostate biopsy are based on cut-off levels of stand-alone markers such as prostate-specific antigen (PSA) or any of its derivatives. Howev...
Intraperitoneal follicular dendritic cell sarcoma: role of chemotherapy and bone marrow allotransplantation in locally advanced disease? [0.03%]
腹腔内滤泡性树突细胞源性恶性肿瘤的化疗及骨髓移植治疗价值探讨
G Liberale,K Keriakos,Ma Azerad et al.
G Liberale et al.
We describe a case of a 44 year-old woman diagnosed with follicular dendritic cell sarcoma (FDCS). FDCS is a very rare disease affecting the dendritic antigen presenting cells and is often misdiagnosed. Surgery is considered the best treatm...
Cisplatin, cetuximab, and radiation in locally advanced head and neck squamous cell cancer: a retrospective review [0.03%]
顺铂、西妥昔单抗和放疗治疗局部晚期头颈部鳞状细胞癌的回顾性分析
Prakash Peddi,Runhua Shi,Binu Nair et al.
Prakash Peddi et al.
Efficacy of cisplatin versus cetuximab with radiation in locally advanced head and neck cancer (LAHNC) was evaluated. A total of 96 patients with newly diagnosed LAHNC treated at our institution between 2006 and 2011 with concurrent radiati...
Antti Jekunen
Antti Jekunen
A new era of medicine is rapidly approaching, which will change not only pathological diagnosis but also medical decision-making. This paper raises the question of how well prepared doctors are to address the new issues that will soon confr...
Changes in protein level in the cerebrospinal fluid of a patient with cerebral radiation necrosis treated with bevacizumab [0.03%]
贝伐单抗治疗放射性脑坏死患者脑脊液中蛋白质水平的变化
Hirohito Yano,Noriyuki Nakayama,Kasumi Morimitsu et al.
Hirohito Yano et al.
A 32-year-old woman underwent surgeries and radiation therapy for astrocytoma. She developed symptomatic radiation necrosis in the lesion, which caused hydrocephalus. She initially underwent ventricular drainage, because the protein level i...
Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment [0.03%]
肺癌ROS1重排FISH检测的成本效益分析及对靶向治疗的意义研究
David Parker,Marc-Antoine Belaud-Rotureau
David Parker
Break-apart fluorescence in situ hybridization (FISH) is the gold standard test for anaplastic lymphoma kinase (ALK) gene rearrangement. However, this methodology often is assumed to be expensive and potentially cost-prohibitive given the l...
The use of pharmacogenomics for selection of therapy in non-small-cell lung cancer [0.03%]
非小细胞肺癌的治疗选择中的药物基因组学应用
Nagla A Karim,Hai Bui,Peterson Pathrose et al.
Nagla A Karim et al.
Introduction: Performance status (PS) is the only known clinical predictor of outcome in patients with advanced non-small-cell lung cancer (NSCLC), although pharmacogenomic markers may also correlate with outcome. The aim...
Ghaleb Elyamany,Ali Mattar Alzahrani,Eman Bukhary
Ghaleb Elyamany
Venous thromboembolism (VTE) is a common complication in patients with malignant disease. Emerging data have enhanced our understanding of cancer-associated thrombosis, a major cause of morbidity and mortality in patients with cancer. In ad...
Phase II Clinical Trial of Gefitinib for the Treatment of Chemonaïve Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status [0.03%]
吉非替尼治疗体力状态差的化疗初治晚期非小细胞肺癌患者II期临床研究
Nagla Abdel Karim,Salma Musaad,Ahmad Zarzour et al.
Nagla Abdel Karim et al.
Background: Patients with advanced non-small cell lung cancer (NSCLC) have no curative treatment options; therefore, improving their quality of life (QOL) is an important goal. Gefitinib, an epidermal growth factor recept...